Metformin Increases Sensitivity of Melanoma Cells to Cisplatin by Blocking Exosomal-Mediated miR-34a Secretion

Figure 4

Metformin treatment sensitizes A375 cells to cisplatin via blocking exosomal secretion of miR-34a. Survival of melanoma cell A375 cells (CCK-8 assay). Cells were treated with metformin, followed by control or cisplatin treatment. (two-way ANOVA). (b) Western blotting of cleaved caspase-3 in A375 cells. Cells treated as abovementioned were harvested at indicated time points. β-Actin served as internal reference. Data were representative of 3 independent experiments. (c) Survival of melanoma cell (A375 cells) (CCK-8 assay). Cells transfected with NC or miR-34a inhibitor were additionally treated with control or metformin/cisplatin treatment. (two-way ANOVA). (d) Western blotting of cleaved caspase-3 in A375 cells. Cells transfected with NC or miR-34a inhibitor were additionally treated with control or metformin/cisplatin treatment. β-Actin served as internal reference. Data are representatives of 3 independent experiments.

(a)

(b)

(c)

(d)